Covista Inc.: Form 10-Q for the period ended Mar 31, 2026
Filed with the SEC on May 7, 2026 and accepted by EDGAR at May 7, 2026, 16:18 ET.
Management's discussion and analysis
As filed, 72,639 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto included in this report. It should also be read in conjunction with our consolidated financial statements and the related Management’s Discussion and Analysis of Financial Condition and Results of Operation as contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K), the Cautionary Disclosure Regarding Forward-Looking Statements, the Risk Factors included in the 2025 Form 10-K, and the Financial Aid and Legislative and Regulatory Requirements disclosures set forth in this report. Covista reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended March 31, 2026 is for our third quarter of fiscal year 2026.
Throughout this MD&A, we sometimes use information derived from the Consolidated Financial Statements and the notes thereto but not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Certain of these items are considered “non-GAAP financial measures” under the Securities and Exchange Commission (“SEC”) rules. See the “Non-GAAP Financial Measures and Reconciliations” section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures.
Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands. Discussions throughout this MD&A are based on continuing operations unless otherwise noted.
Available Information
We use our website (www.covista.com (http://www.covista.com)) as a routine channel of distribution of company information, including press releases, presentations, and supplemental information, as one means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, you should monitor our website in addition to following press releases, SEC filings, and public conference calls and webcasts. You can receive notifications of new information posted on our investor relations website in real time by signing up for email alerts. You may also access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, as well as other reports relating to us that are filed with or furnished to the SEC, free of charge in the investor relations section of our website as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov (http://www.sec.gov). The content of the websites mentioned above is not incorporated into and should not be considered a part of this report.
Segments
We present three reportable segments as follows:
Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.
Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry.
“Home Office” includes activities not allocated to a reportable segment. Financial and descriptive information about Covista’s reportable segments is presented in Note 18 “Segment Information” to the Consolidated Financial Statements.
Third Quarter Highlights
Financial and operational highlights for the third quarter of fiscal year 2026 include:
- Covista revenue increased 4.5%, or $21.0 million, to $487.0 million in the third quarter of fiscal year 2026 compared to the prior year period driven by increased revenue across all of our segments. Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026.
- Net income decreased 31.6%, or $19.2 million, to $41.6 million in the third quarter of fiscal year 2026 compared to the prior year period. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The net income decrease was also driven by a loss from discontinued operations and increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives, partially offset by a reduction in asset impairments.
- Diluted earnings per share decreased 24.5%, or $0.39, to $1.20 in the third quarter of fiscal year 2026 compared to the prior year period driven by the decrease in net income, partially offset by lower diluted shares due to share repurchases.
- Adjusted net income decreased 5.8%, or $4.2 million, to $69.0 million in the third quarter of fiscal year 2026 compared to the prior year period. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted net income decrease was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
- Adjusted earnings per share increased 3.1%, or $0.06, to $1.98 in the third quarter of fiscal year 2026 compared to the prior year period driven by lower diluted shares due to share repurchases, partially offset by the decrease in adjusted net income.
- For the January 2026 and March 2026 sessions, total student enrollment at Chamberlain decreased 0.7% and increased 0.5%, respectively, compared to the same sessions last year.
- As of March 31, 2026, total student enrollment at Walden increased 12.3% compared to March 31, 2025.
- For the January 2026 semester, total student enrollment at the medical and veterinary schools increased 4.1% compared to the same semester last year.
- On March 2, 2026, we entered into Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement (the “Term Loan B Amendment”) to incur new term loans under Term Loan B in an aggregate principal amount of $510.0 million with a maturity date of March 2, 2033. In addition, on March 2, 2026, we repaid the previously outstanding $103.3 million principal amount of Term Loan B and the remaining $405.0 million outstanding principal amount of the Senior Secured Notes due 2028. See Note 13 “Debt” to the Consolidated Financial Statements for additional information.
- Covista repurchased a total of 637,538 shares of its common stock under its share repurchase programs at an average cost of $103.04 per share during the third quarter of fiscal year 2026. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors.
Results of Operations
Revenue
The following tables present revenue by segment detailing the changes from the prior year periods (in thousands):
| | | Three Months Ended March 31, 2026 Chamberlain | Walden (1) | Medical and Veterinary | Consolidated (1) |
|---|---|---|---|---|---|
| Fiscal year 2025 | | $192,592 | $178,418 | $95,045 | $466,055 |
| Growth | | 4,371 | 8,157 | 8,447 | 20,975 |
| Fiscal year 2026 | | $196,963 | $186,575 | $103,492 | $487,030 |
| % change from prior year | | 2.3% | 4.6% | 8.9% | 4.5% |
| | | Nine Months Ended March 31, 2026 Chamberlain | Walden | Medical and Veterinary | Consolidated |
|---|---|---|---|---|---|
| Fiscal year 2025 | | $541,508 | $511,237 | $278,439 | $1,331,184 |
| Growth | | 18,488 | 82,860 | 20,171 | 121,519 |
| Fiscal year 2026 | | $559,996 | $594,097 | $298,610 | $1,452,703 |
| % change from prior year | | 3.4% | 16.2% | 7.2% | 9.1% |
(1) Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden segment revenue would have increased 14.7%, or $26.2 million, to $204.6 million and consolidated revenue would have increased 8.4%, or $39.0 million, to $505.0 million.
Chamberlain
Chamberlain Student Enrollment:
| Session | | Fiscal Year 2026 July 2025 Sept. 2025 Nov. 2025 Jan. 2026 Mar. 2026 |
|---|---|---|
| Total students | | 37,697 39,846 39,278 40,145 40,767 |
| % change from prior year | | 4.5% 2.2% (1.0)% (0.7)% 0.5% |
| | | |
| | | Fiscal Year 2025 |
| Session | | July 2024 Sept. 2024 Nov. 2024 Jan. 2025 Mar. 2025 May 2025 |
| Total students | | 36,061 38,987 39,691 40,445 40,564 38,891 |
| % change from prior year | | 12.1% 11.7% 11.5% 8.7% 6.8% 5.8% |
Chamberlain revenue increased 2.3%, or $4.4 million, to $197.0 million in the third quarter and increased 3.4%, or $18.5 million, to $560.0 million in the first nine months of fiscal year 2026 compared to the prior year periods. The increase in revenue in the third quarter of fiscal year 2026 was driven by higher tuition rates and increased enrollment in the March session as increases in pre-licensure nursing program enrollment more than offset declines in post-licensure nursing program enrollment. The increase in revenue in the first nine months of fiscal year 2026 was driven by higher tuition rates and enrollment. Enrollment increased in pre-licensure nursing programs in all fiscal year 2026 sessions; however, enrollment has declined in post-licensure nursing programs during fiscal year 2026. Chamberlain is achieving pre-licensure growth by optimizing investments in student enrollment and experience while leveraging scale through a national footprint with in-person and online curriculum delivery modalities. Management is focused on optimizing marketing and enrollment operations to address post-licensure enrollment.
Tuition Rates:
Tuition rates in the current fiscal year increased in January 2026 compared to the prior fiscal year for the Bachelor of Science in Nursing (“BSN”) onsite and online degree, Master of Science in Nursing (“MSN”), Master of Social Work (“MSW”) and Master of Public Health (“MPH”) online degree programs. The average increase across all of these programs was approximately 3.3% from the prior year.
Walden
Walden Student Enrollment:
| Period | | Fiscal Year 2026 Sept. 30, Dec. 31, Mar. 31, 2025 2025 2026 |
|---|---|---|
| Total students | | 52,216 52,435 54,474 |
| % change from prior year | | 13.6% 13.0% 12.3% |
| | | |
| | | Fiscal Year 2025 |
| | | Sept. 30, Dec. 31, Mar. 31, June 30, |
| Period | | 2024 2024 2025 2025 |
| Total students | | 45,979 46,399 48,526 48,116 |
| % change from prior year | | 12.2% 13.2% 13.5% 15.0% |
Walden total student enrollment represents those students attending instructional sessions as of the dates identified above. Walden revenue increased 4.6%, or $8.2 million, to $186.6 million in the third quarter and increased 16.2%, or $82.9 million, to $594.1 million in the first nine months of fiscal year 2026 compared to the prior year periods, driven by an increase in enrollment, higher tuition rates, and an increase in average credit hours per student. Walden revenue for the third quarter of fiscal year 2026 was impacted by the shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Walden’s improved enrollment has been accelerated by investments in student experience and brand along with providing flexibility to working adults through part-time and Tempo Learning® competency-based programs.
Tuition Rates:
Tuition rates for Walden programs, including general education are charged on a per credit hour basis that varies based on the nature of the program. For other programs such as those with a subscription-based learning modality, tuition is charged on a per term basis. Students are also charged program and clinical fees depending on the specific programs. Some programs require students to attend residencies, skills labs, and pre-practicum labs, for which tuition is charged per event. In most programs, these tuition rates, event charges, and fees increased by approximately 2.6% from the prior year.
Medical and Veterinary
Medical and Veterinary Student Enrollment:
| Semester | | Fiscal Year 2026 Sept. 2025 Jan. 2026 |
|---|---|---|
| Total students | | 5,297 5,344 |
| % change from prior year | | 2.4% 4.1% |
| | | |
| | | Fiscal Year 2025 |
| Semester | | Sept. 2024 Jan. 2025 May 2025 |
| Total students | | 5,174 5,133 4,773 |
| % change from prior year | | (0.7)% 1.2% 1.0% |
Medical and Veterinary revenue increased 8.9%, or $8.4 million, to $103.5 million in the third quarter and increased 7.2%, or $20.2 million, to $298.6 million in the first nine months of fiscal year 2026 compared to the prior year periods, driven by an increase in enrollment and higher tuition rates. Management continues to focus on increasing enrollment and driving operational effectiveness, specifically around academic support and the enrollment experience.
Tuition Rates:
- Effective for semesters beginning in September 2025, tuition rates and administrative fees for the basic sciences and clinical rotation portions of AUC’s medical program increased 4.5% from the prior academic year.
- Effective for semesters beginning in September 2025, tuition rates and administrative fees for the basic sciences and clinical rotation portions of RUSM’s medical program increased 4.5% and 4.6%, respectively, from the prior academic year.
- Effective for semesters beginning in September 2025, tuition rates for the pre-clinical and clinical curriculum of RUSVM’s veterinary program increased 3.0% from the prior academic year.
Cost of Educational Services
The cost of educational services expense category includes expenses related to the cost of faculty and staff who support educational operations, facilities, adjunct faculty, supplies, housing, bookstore, other educational materials, student education-related support activities, and provision for bad debts. The following tables present cost of educational services by segment detailing the changes from the prior year periods (in thousands):
| | Three Months Ended March 31, 2026 Chamberlain | Walden | Medical and Veterinary | Consolidated |
|---|---|---|---|---|
| Fiscal year 2025 | $83,397 | $62,105 | $54,367 | $199,869 |
| Cost increase | 1,542 | 8,173 | 1,135 | 10,850 |
| Fiscal year 2026 | $84,939 | $70,278 | $55,502 | $210,719 |
| % change from prior year | 1.8% | 13.2% | 2.1% | 5.4% |
| | Nine Months Ended March 31, 2026 Chamberlain | Walden | Medical and Veterinary | Consolidated |
|---|---|---|---|---|
| Fiscal year 2025 | $237,120 | $177,799 | $157,581 | $572,500 |
| Cost increase | 17,085 | 23,964 | 3,362 | 44,411 |
| Fiscal year 2026 | $254,205 | $201,763 | $160,943 | $616,911 |
| % change from prior year | 7.2% | 13.5% | 2.1% | 7.8% |
Cost of educational services increased 5.4%, or $10.9 million, to $210.7 million in the third quarter and increased 7.8%, or $44.4 million, to $616.9 million in the first nine months of fiscal year 2026 compared to the prior year periods. The cost increase in the third quarter and first nine months of fiscal year 2026 was primarily driven by an increase in labor and other costs to support increased enrollment.
As a percentage of revenue, cost of educational services was 43.3% and 42.5% in the third quarter and first nine months of fiscal year 2026, respectively, compared to 42.9% and 43.0% in the prior year periods. The increase in the percentage for the third quarter of fiscal year 2026 was primarily the result of the $18.0 million impact on Walden revenue due to the shift of one academic week from the third quarter to the second quarter of fiscal year 2026. The decrease in the percentage for the first nine months of fiscal year 2026 was primarily the result of revenue growth accompanied by cost efficiencies.
Student Services and Administrative Expense
The student services and administrative expense category includes expenses related to student admissions, marketing and advertising, general and administrative, and amortization of acquired intangible assets. The following tables present student services and administrative expense by segment detailing the changes from the prior year periods (in thousands):
| | | Three Months Ended March 31, 2026 Chamberlain | Walden | Medical and Veterinary | Home Office | Consolidated |
|---|---|---|---|---|---|---|
| Fiscal year 2025 | | $61,702 | $71,119 | $22,757 | $19,589 | $175,167 |
| Cost increase | | 2,427 | 5,607 | 3,731 | 1,478 | 13,243 |
| Asset impairments decrease | | — | — | — | (6,442) | (6,442) |
| Strategic advisory costs increase | | — | — | — | 2,138 | 2,138 |
| Fiscal year 2026 | | $64,129 | $76,726 | $26,488 | $16,763 | $184,106 |
| | | | | | | |
| Fiscal year 2026 % change: | | | | | | |
| Cost increase | | 3.9% | 7.9% | 16.4% | 7.5% | 7.6% |
| Asset impairments decrease | | — | — | — | (32.9)% | (3.7)% |
| Strategic advisory costs increase | | — | — | — | 10.9% | 1.2% |
| Fiscal year 2026 % change | | 3.9% | 7.9% | 16.4% | (14.4)% | 5.1% |
| | | Nine Months Ended March 31, 2026 Chamberlain | Walden | Medical and Veterinary | Home Office | Consolidated |
|---|---|---|---|---|---|---|
| Fiscal year 2025 | | $186,760 | $199,509 | $66,688 | $38,184 | $491,141 |
| Cost increase | | 11,705 | 18,780 | 7,670 | 3,007 | 41,162 |
| Litigation reserve impact | | — | 5,550 | — | — | 5,550 |
| Asset impairments decrease | | — | — | — | (6,442) | (6,442) |
| Strategic advisory costs increase | | — | — | — | 11,932 | 11,932 |
| Debt modification costs decrease | | — | — | — | (712) | (712) |
| Fiscal year 2026 | | $198,465 | $223,839 | $74,358 | $45,969 | $542,631 |
| | | | | | | |
| Fiscal year 2026 % change: | | | | | | |
| Cost increase | | 6.3% | 9.4% | 11.5% | 7.9% | 8.4% |
| Litigation reserve impact | | — | 2.8% | — | — | 1.1% |
| Asset impairments decrease | | — | — | — | (16.9)% | (1.3)% |
| Strategic advisory costs increase | | — | — | — | 31.2% | 2.4% |
| Debt modification costs decrease | | — | — | — | (1.9)% | (0.1)% |
| Fiscal year 2026 % change | | 6.3% | 12.2% | 11.5% | 20.4% | 10.5% |
Student services and administrative expense increased 5.1%, or $8.9 million, to $184.1 million in the third quarter and increased 10.5%, or $51.5 million, to $542.6 million in the first nine months of fiscal year 2026 compared to the prior year periods. After excluding asset impairments and strategic advisory costs, student services and administrative expense increased 7.6%, or $13.2 million, in the third quarter of fiscal year 2026 compared to the prior year period. After excluding litigation reserve, asset impairments, strategic advisory costs, and debt modification costs, student services and administrative expense increased 8.4%, or $41.2 million, in the first nine months of fiscal year 2026 compared to the prior year period. These increases were primarily driven by an increase in marketing expense and investments to support growth initiatives.
As a percentage of revenue, student services and administrative expense was 37.8% and 37.4% in the third quarter and first nine months of fiscal year 2026, respectively, compared to 37.6% and 36.9% in the prior year periods. The increase in the percentage for the third quarter of fiscal year 2026 was primarily the result of the $18.0 million impact on Walden revenue due to the shift of one academic week from the third quarter to the second quarter of fiscal year 2026. The increase in the percentage for the first nine months of fiscal year 2026 was primarily the result of an increase in strategic advisory costs in the current year period and a reduction in litigation reserves in the prior year period, partially offset by revenue growth in the current year period. The reduction in litigation reserves in fiscal year 2025 represented a $5.6 million receipt in the second quarter of fiscal year 2025 from a claim made for indemnification under the Membership Interest Purchase Agreement with Laureate Education, Inc.
Restructuring Expense
Restructuring expense was $0.9 million and $5.2 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to $0.5 million and $2.9 million in the prior year periods. The increases in fiscal year 2026 were primarily driven by workforce reductions. In addition, we continue to incur restructuring charges or reversals related to exited leased space from previous restructuring activities.
Operating Income
The following table presents a reconciliation of operating income to adjusted operating income by segment (in thousands):
| Chamberlain: | | Three Months Ended March 31, 2026 | 2025 | Increase/(Decrease) $% | | | | Nine Months Ended March 31, 2026 | 2025 | Increase/(Decrease) $% | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | | $47,696 | $47,516 | $180 | | 0.4% | | $105,302 | $115,716 | $(10,414) | | (9.0)% |
| Restructuring expense | | 199 | (23) | 222 | | | | 2,024 | 1,912 | 112 | | |
| Adjusted operating income | | $47,895 | $47,493 | $402 | | 0.8% | | $107,326 | $117,628 | $(10,302) | | (8.8)% |
| Operating margin | | 24.2% | 24.7% | | | | | 18.8% | 21.4% | | | |
| Adjusted operating margin | | 24.3% | 24.7% | | | | | 19.2% | 21.7% | | | |
| | | | | | | | | | | | | |
| Walden: | | | | | | | | | | | | |
| Operating income | | $39,540 | $45,194 | $(5,654) | | (12.5)% | | $168,035 | $133,929 | $34,106 | | 25.5% |
| Restructuring expense | | 31 | — | 31 | | | | 460 | — | 460 | | |
| Amortization of acquired intangible assets | | 2,805 | 2,805 | — | | | | 8,415 | 8,415 | — | | |
| Litigation reserve | | — | — | — | | | | — | (5,550) | 5,550 | | |
| Adjusted operating income (1) | | $42,376 | $47,999 | $(5,623) | | (11.7)% | | $176,910 | $136,794 | $40,116 | | 29.3% |
| Operating margin | | 21.2% | 25.3% | | | | | 28.3% | 26.2% | | | |
| Adjusted operating margin (1) | | 22.7% | 26.9% | | | | | 29.8% | 26.8% | | | |
| | | | | | | | | | | | | |
| Medical and Veterinary: | | | | | | | | | | | | |
| Operating income | | $21,127 | $17,800 | $3,327 | | 18.7% | | $62,454 | $53,934 | $8,520 | | 15.8% |
| Restructuring expense | | 375 | 121 | 254 | | | | 855 | 236 | 619 | | |
| Adjusted operating income | | $21,502 | $17,921 | $3,581 | | 20.0% | | $63,309 | $54,170 | $9,139 | | 16.9% |
| Operating margin | | 20.4% | 18.7% | | | | | 20.9% | 19.4% | | | |
| Adjusted operating margin | | 20.8% | 18.9% | | | | | 21.2% | 19.5% | | | |
| | | | | | | | | | | | | |
| Home Office: | | | | | | | | | | | | |
| Operating loss | | $(17,021) | $(20,001) | $2,980 | | 14.9% | | $(47,858) | $(38,962) | $(8,896) | | (22.8)% |
| Restructuring expense | | 258 | 412 | (154) | | | | 1,889 | 778 | 1,111 | | |
| Asset impairments | | — | 6,442 | (6,442) | | | | — | 6,442 | (6,442) | | |
| Strategic advisory costs | | 7,238 | 5,100 | 2,138 | | | | 17,032 | 5,100 | 11,932 | | |
| Debt modification costs | | — | — | — | | | | — | 712 | (712) | | |
| Adjusted operating loss | | $(9,525) | $(8,047) | $(1,478) | | (18.4)% | | $(28,937) | $(25,930) | $(3,007) | | (11.6)% |
| | | | | | | | | | | | | |
| Covista: | | | | | | | | | | | | |
| Operating income (GAAP) (1) | | $91,342 | $90,509 | $833 | | 0.9% | | $287,933 | $264,617 | $23,316 | | 8.8% |
| Restructuring expense | | 863 | 510 | 353 | | | | 5,228 | 2,926 | 2,302 | | |
| Amortization of acquired intangible assets | | 2,805 | 2,805 | — | | | | 8,415 | 8,415 | — | | |
| Litigation reserve | | — | — | — | | | | — | (5,550) | 5,550 | | |
| Asset impairments | | — | 6,442 | (6,442) | | | | — | 6,442 | (6,442) | | |
| Strategic advisory costs | | 7,238 | 5,100 | 2,138 | | | | 17,032 | 5,100 | 11,932 | | |
| Debt modification costs | | — | — | — | | | | — | 712 | (712) | | |
| Adjusted operating income (non-GAAP) (1) | | $102,248 | $105,366 | $(3,118) | | (3.0)% | | $318,608 | $282,662 | $35,946 | | 12.7% |
| Operating margin (GAAP) (1) | | 18.8% | 19.4% | | | | | 19.8% | 19.9% | | | |
| Adjusted operating margin (non-GAAP) (1) | | 21.0% | 22.6% | | | | | 21.9% | 21.2% | | | |
(1) Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden adjusted operating income would have increased 25.8%, or $12.4 million, to $60.4 million and Walden adjusted operating margin would have been 29.5%. Similarly, consolidated operating income would have increased 20.8%, or $18.8 million, to $109.4 million and consolidated adjusted operating income would have increased 14.1%, or $14.9 million, to $120.3 million. Consolidated operating margin would have been 21.7% and consolidated adjusted operating margin would have been 23.8%.
Consolidated operating income increased 0.9%, or $0.8 million, to $91.3 million in the third quarter and increased 8.8%, or $23.3 million, to $287.9 million in the first nine months of fiscal year 2026 compared to the prior year periods. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The operating income increase in the third quarter of fiscal year 2026 was also driven by a reduction in asset impairments, partially offset by increases in strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives. The operating income increase in the first nine months of fiscal year 2026 was primarily driven by an increase in revenue and a reduction in asset impairments, partially offset by a reduction in litigation reserves in the prior year period, and increases in strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Consolidated adjusted operating income decreased 3.0%, or $3.1 million, to $102.2 million in the third quarter and increased 12.7%, or $35.9 million, to $318.6 million in the first nine months of fiscal year 2026 compared to the prior year periods. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted operating income decrease in the third quarter of fiscal year 2026 was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives. The adjusted operating income increase in the first nine months of fiscal year 2026 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Chamberlain
Segment adjusted operating income increased 0.8%, or $0.4 million, to $47.9 million in the third quarter and decreased 8.8%, or $10.3 million, to $107.3 million in the first nine months of fiscal year 2026 compared to the prior year periods. The adjusted operating income increase in the third quarter of fiscal year 2026 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs of educational services, marketing expense, and investments to support growth initiatives. The adjusted operating income decrease in the first nine months of fiscal year 2026 was primarily driven by increases in labor and other costs of educational services, marketing expense, and investments to support growth initiatives, partially offset by an increase in revenue.
Walden
Segment adjusted operating income decreased 11.7%, or $5.6 million, to $42.4 million in the third quarter and increased 29.3%, or $40.1 million, to $176.9 million in the first nine months of fiscal year 2026 compared to the prior year periods. While Walden revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted operating income decrease in the third quarter of fiscal year 2026 was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives. The adjusted operating income increase in the first nine months of fiscal year 2026 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Medical and Veterinary
Segment adjusted operating income increased 20.0%, or $3.6 million, to $21.5 million in the third quarter and increased 16.9%, or $9.1 million, to $63.3 million in the first nine months of fiscal year 2026 compared to the prior year periods. The adjusted operating income increases in the third quarter and first nine months of fiscal year 2026 were primarily driven by an increase in revenue, partially offset by increases in investments to support initiatives to drive growth, investments in academic support, and marketing expense.
Interest Expense
Interest expense was $13.6 million and $35.6 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to $13.1 million and $41.5 million in the prior year periods. The interest expense increase in the third quarter of fiscal year 2026 was primarily driven by an increase in a loss on debt extinguishment from the write-off of debt issuance costs (as discussed in Note 13 “Debt” to the Consolidated Financial Statements). The interest expense decrease in the first nine months of fiscal year 2026 was primarily driven by lower interest expense due to decreased borrowings and a lower interest rate on our Term Loan B, and lower outstanding letters of credit balances during the period, partially offset by an increase in a loss on debt extinguishment from the write-off of debt issuance costs.
Other Income, Net
Other income, net was $0.2 million and $4.4 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to $1.9 million and $6.8 million in the prior year periods. The decrease in the third quarter of fiscal year 2026 was primarily driven by a decrease in interest income driven by lower invested cash balances and higher investment losses. The decrease in the first nine months of fiscal year 2026 was primarily driven by a decrease in interest income driven by lower invested cash balances, partially offset by higher investment gains.
Provision for Income Taxes
Our effective income tax rate from continuing operations can differ from the 21% U.S. federal statutory rate due to several factors, including tax on global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, changes in uncertain tax positions, and tax benefits on stock-based compensation.
Our effective tax rate from continuing operations was 25.6% and 24.0% in the third quarter and first nine months of fiscal year 2026, respectively, and 23.4% and 22.5% in the third quarter and first nine months of fiscal year 2025, respectively. The effective tax rate for the third quarter of fiscal year 2026 increased compared to the prior year period primarily due to an increase in the limitation of tax benefits on certain executive compensation, partially offset by a decrease in the percentage of earnings from operations in higher taxed jurisdictions. The effective tax rate for the first nine months of fiscal year 2026 increased compared to the prior year period primarily due to an increase in the limitation of tax benefits on certain executive compensation, partially offset by a decrease in the percentage of earnings from operations in higher taxed jurisdictions and an increase in tax benefits on stock-based compensation.
In July 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which introduced substantial changes to U.S. tax provisions. The most relevant provisions to Covista for fiscal year 2026 include allowing accelerated tax deductions for qualified property and research and development expenditures. The impacts of OBBBA were not material to the income tax provision for the third quarter and nine months ended March 31, 2026.
Discontinued Operations
We had a loss from discontinued operations of $16.3 million and $15.4 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to income of $0.04 million and $4.6 million in the prior year periods. We recorded income within discontinued operations related to the DeVry University earn-out of $0.5 million and $7.0 million in the first nine months of fiscal year 2026 and 2025, respectively. In addition, we continue to have activity associated with ongoing litigation and settlements related to divestitures, which is classified within discontinued operations.
Financial Aid
Like other higher education institutions, Covista’s institutions are dependent upon the timely receipt of federal financial aid funds. All public financial aid programs are subject to political and governmental budgetary considerations. Covista’s institutions and their students participate in a wide range of financial aid programs, including U.S. federal financial aid, state financial aid, Canadian financial aid, private loan programs, tax-favored programs, Covista-provided financial assistance, and employer-provided financial assistance. In the U.S., the Higher Education Act (as reauthorized, the “HEA”) guides the federal government’s support of postsecondary education. Changes to financial aid programs that restrict student eligibility or reduce funding levels could have a material adverse effect on Covista’s business, financial condition, results of operations, and cash flows. See Item 1A. “Risk Factors” in our 2025 Form 10-K for a discussion of student financial aid related risks.
Legislative and Regulatory Requirements
Government-funded financial assistance programs are governed by extensive and complex regulations in the U.S. Like any other educational institution, Covista’s institutions’ administration of these programs is periodically reviewed by regulatory agencies and is subject to audit or investigation by other authorities. Any violation could be the basis for penalties or other disciplinary action, including initiation of a suspension, limitation, or termination proceeding.
Financial Responsibility
Institutions must pass an ED financial responsibility test, also known as a “composite score,” to maintain eligibility to participate in Title IV aid programs. For Covista’s institutions, this test is calculated at the consolidated Covista level. Applying various financial elements from annual audited financial statements, the score is a composite of three ratios: an equity ratio that measures the institution’s capital resources; a primary reserve ratio that measures an institution’s ability to fund its operations from current resources; and a net income ratio that measures an institution’s ability to operate profitably. A score greater than or equal to 1.5 indicates the institution is considered financially responsible. A score less than 1.5 but greater than or equal to 1.0 is considered financially responsible but requires additional oversight. For example, an institution with a score in this range is subject to heightened cash monitoring and other participation requirements. An institution with a score of less than 1.0 is not considered financially responsible but may continue to participate in the Title IV programs under provisional certification. In addition, this lower score typically requires that the institution be subject to heightened cash monitoring requirements and post a letter of credit (equal to a minimum of 10% of the Title IV aid it received in the institution's most recent fiscal year).
Prior to fiscal year 2022, Covista’s composite score was greater than 1.5. However, on September 25, 2023, ED notified Covista that its fiscal year 2022 composite score had declined to 0.2. As previously disclosed, this was expected due to the acquisition of Walden and other transactions. ED advised that Covista’s five institutions will be permitted to continue to participate in Title IV under provisional certifications with heightened cash monitoring and continued reporting. Management does not believe these conditions will have a material adverse effect on Covista’s operations. At ED’s request, Covista maintains surety-backed letters of credit in favor of ED totaling $202.6 million representing 10% of the consolidated Title IV funds Covista’s institutions received during fiscal year 2025. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements for additional information.
The financial responsibility rules include other mandatory or discretionary triggers that could require an institution to post a letter of credit. ED recently amended the financial responsibility regulation and the changes took effect July 1, 2024. The changes include additional triggers which could require additional letters of credit.
Program Participation Agreement (“PPA”)
The HEA specifies the manner in which ED reviews institutions for eligibility and certification to participate in Title IV programs. Every educational institution participating in Title IV programs must be certified to participate through a PPA and certification must be periodically renewed. Such recertification generally is required every six years, but may be required earlier, including when an institution undergoes a change in control. Institutions that violate certain ED Title IV regulations may lose eligibility to participate in Title IV programs or may only continue participation under provisional certification. ED may place an institution on provisional certification status if it finds that the institution does not fully satisfy all of the eligibility and certification standards and in certain other circumstances, such as when an institution is certified for the first time or undergoes a change in control. During the period of provisional certification, the institution must comply with any additional conditions included in the institution’s PPA. In addition, ED may more closely review an institution that is provisionally certified if it applies for recertification or approval to open a new location, add an educational program, acquire another institution, or make any other significant change. Students attending provisionally certified institutions remain eligible to receive Title IV program funds. Provisional certification status also carries fewer due process protections than full certification. If ED determines that a provisionally certified institution is unable to meet its responsibilities under its PPA, it may seek to revoke the institution’s certification to participate in Title IV programs without advance notice or opportunity for the institution to challenge the action.
In February 2026, ED provisionally recertified Chamberlain’s PPA through December 31, 2028.
ED provisionally recertified Walden’s Title IV PPA through December 31, 2028.
In March 2026, ED provisionally recertified AUC’s PPA through December 31, 2028.
ED last provisionally recertified RUSM’s Title IV PPA through March 31, 2025. Title IV regulations relative to the recertification process allow for an institution’s continued participation in the Title IV programs until its application is either approved or not approved, provided a materially complete application is submitted by the institution no later than 90 days prior to the expiration date in its PPA. This is true even if ED does not complete its evaluation of the application before the PPA’s expiration date. A materially complete application for RUSM’s PPA recertification was timely submitted to ED, which has allowed for RUSM’s unhampered continued access to Title IV funding after PPA expiration.
ED provisionally recertified RUSVM’s Title IV PPA through March 31, 2027.
The provisional nature of the PPAs stemmed from Covista’s composite score declining and failing to meet ED’s standards of financial responsibility as described above.
Walden, AUC, RUSM, and RUSVM’s provisional PPAs included financial requirements, such as letter of credit and heightened cash monitoring, and RUSM and RUSVM’s provisional PPAs require additional reporting. We do not believe these requirements will have a material effect on Covista’s financial condition or results of operations.
Gainful Employment
The HEA requires certificate programs at all Title IV institutions and degree programs at proprietary Title IV institutions to prepare students for gainful employment in a recognized occupation. In October 2023, ED released new Financial Value Transparency (“FVT”) and Gainful Employment (“GE”) rules effective July 1, 2024. GE programs must meet a debt-to-earnings test in which graduates’ annual debt payments must not exceed 8% of their annual earnings or 20% of their discretionary earnings. GE programs must also meet an earnings premium test in which graduates’ earnings must exceed those of a typical high school graduate. Under the regulation, programs that fail either metric must provide warnings to students and prospective students that the program is at risk of losing Title IV eligibility and programs that fail the same measure in two out of three consecutive years lose Title IV eligibility. The GE regulation also includes a transparency framework in which debt-to-earnings, earnings premium, and a wide range of other program outcomes for all Title IV programs are disclosed on a website hosted by ED. Because there are many factors and unknowns, including the earnings of program graduates, Covista is reviewing the regulation to determine what impact, if any, the regulation will have on its programs. In addition, multiple parties sought to block enforcement of the FVT/GE rule under the Administrative Procedure Act and other legal theories. On October 2, 2025, a federal district judge ruled in ED’s favor, upholding the FVT/GE rules. The decision is subject to appeal. On February 14, 2025, ED extended the institutional reporting deadline for 2023-2024 and earlier award years until September 30, 2025. The reporting deadline for the 2024-2025 award year was October 1, 2025. On July 25, 2025, ED announced its intent to establish negotiated rulemaking committees in advance of issuing draft regulations on various topics, including FVT/GE. The negotiating committee addressing FVT/GE met in December 2025 and January 2026. ED’s initial proposal includes amendments to the FVT/GE rules including elimination of debt to earnings.
Do No Harm
The recently enacted Do No Harm provisions of OBBBA provide that an undergraduate program may lose Title IV eligibility if the earnings of a programmatic cohort of its completers as defined in OBBBA are no greater than earnings of a population with a high school diploma, and a graduate or professional program may lose Title IV eligibility if the earnings of a programmatic cohort of its completers as defined in OBBBA and its implementing regulations are no greater than the earnings of a population with a bachelor’s degree, in each case for two years in a three-year period. These provisions are applicable to all Title IV participating institutions. Regulations to define how Do No Harm will be implemented, including the definition of completer, the populations to be used to measure the difference between earnings of completers and earnings of others, have yet to be promulgated. On July 25, 2025, ED announced its intent to establish negotiated rulemaking committees to implement Do No Harm and other provisions of OBBBA. The negotiating committee met in December 2025 and January 2026.
The 90/10 Rule
An ED regulation known as the 90/10 Rule affects only proprietary institutions participating in Title IV programs, including each of Covista’s institutions. Under this regulation, an institution that derives more than 90% of its revenue on a cash basis from Federal education assistance funds in two consecutive fiscal years loses eligibility to participate in Title IV programs. The following table shows the 90/10 rates for each Covista institution for fiscal year 2025 and fiscal year 2024. A consolidated rate for Covista is also provided even though it is not subject to 90/10 requirements.
| | Fiscal Year 2025 | 2024 |
|---|---|---|
| Chamberlain University | 70% | 68% |
| Walden University | 82% | 82% |
| American University of the Caribbean School of Medicine | 86% | 87% |
| Ross University School of Medicine | 86% | 87% |
| Ross University School of Veterinary Medicine | 77% | 78% |
| Consolidated | 78% | 77% |
Borrower Defense to Repayment
Under the HEA, ED is authorized to specify acts or omissions of an institution that a borrower may assert as a Borrower Defense to Repayment (“BDR”) of their Title IV loans made under the Federal Direct Loan Program. The 2022 BDR regulations were scheduled to go into effect on July 1, 2023 that included a lower threshold for establishing misrepresentation, no statute of limitation for claims submission, expanded reasons to file a claim including aggressive or deceptive recruitment tactics and omission of fact, weakened due processes afforded to institutions, and reinstated provisions for group discharges. ED also included a six-year statute of limitations for recovery of funds from institutions. These changes would increase financial liability risk and reputational risk for Covista. However, the updated rules were delayed by litigation from another party and the July 2025 enactment of OBBBA, which restored the 2019 BDR regulations and delayed the 2022 regulations until July 1, 2035. Consequently, on August 8, 2025, the parties in the litigation dismissed the appeal of the preliminary injunction order, returning the merits of the case to the district court.
Liquidity and Capital Resources
Covista’s primary source of liquidity is the cash received from payments for student tuition, fees, books, and other educational materials. These payments include funds originating as financial aid from various federal and state loan and grant programs, student and family educational loans, employer educational reimbursements, scholarships, and student and family financial resources. Covista continues to provide financing options for its students, including Covista’s credit extension programs.
The pattern of cash receipts during the year is seasonal. Covista’s cash collections on accounts receivable peak at the start of each institution’s term. Accounts receivable reach their lowest level at the end of each institution’s term.
Covista’s consolidated cash and cash equivalents balance of $147.0 million and $199.6 million as of March 31, 2026 and June 30, 2025, respectively, included cash and cash equivalents held at Covista’s international operations of $3.3 million and $22.9 million as of March 31, 2026 and June 30, 2025, respectively, which is available to Covista for general corporate purposes.
Cash Flow Summary
Operating Activities
Net cash provided by operating activities from continuing operations in the nine months ended March 31, 2026 increased $72.6 million to $346.4 million, compared to $273.8 million in the prior year period. This increase was primarily driven by a $125.3 million increase in cash collected from students, a $22.9 million decrease in net legal settlement payments, a $6.8 million decrease in interest payments, and a $2.3 million decrease in income tax payments, partially offset by a $82.1 million increase in payments to employees and vendors.
Investing Activities
Net cash used in investing activities in the nine months ended March 31, 2026 and 2025 was $55.9 million and $30.3 million, respectively, and was primarily driven by capital expenditures of $50.9 million and $31.3 million, respectively. In addition, during the nine months ended March 31, 2026, we made a $5.0 million minority investment in a business. Capital expenditures for fiscal year 2026 primarily include information technology investments and new campus development at Chamberlain.
Financing Activities
Net cash used in financing activities in the nine months ended March 31, 2026 was $342.9 million, primarily driven by share repurchases of $239.9 million, net repayments under long-term debt obligations of $50.8 million, and employee taxes paid on withholding shares of $42.1 million. Net cash used in financing activities in the nine months ended March 31, 2025 was $248.0 million, primarily driven by share repurchases of $146.4 million and net repayments under long-term debt obligations of $100.0 million.
On December 15, 2025, we announced that the Board authorized Covista’s sixteenth share repurchase program, which allows Covista to repurchase up to $750.0 million of its common stock through December 15, 2028. As of March 31, 2026, $661.8 million of authorized share repurchases remained under the sixteenth share repurchase program. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. See Note 14 “Share Repurchases” to the Consolidated Financial Statements for additional information on our share repurchase programs.
Material Cash Requirements
Long-Term Debt – As of March 31, 2026, Covista had a Term Loan B principal amount of $510.0 million under its Credit Facility, which matures on March 2, 2033 and requires quarterly interest payments. See Note 13 “Debt” to the Consolidated Financial Statements for additional information on our Credit Facility.
As of March 31, 2026, Covista had $202.6 million of surety-backed letters of credit outstanding in favor of ED. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements for additional information.
As of March 31, 2026, Covista had $76.9 million of surety bonds to satisfy certain state regulatory requirements for licensure.
In the event of unexpected market conditions or negative economic changes that could negatively affect Covista’s earnings and/or operating cash flow, our Credit Facility includes a $500.0 million revolving credit facility with available capacity of $500.0 million as of March 31, 2026.
Operating Lease Obligations – We have operating lease obligations for the minimum payments required under various lease agreements which are recorded on the Consolidated Balance Sheets. See Note 11 “Leases” to the Consolidated Financial Statements for additional information on our lease obligations.
We believe our cash flows from operations, and our existing cash balances, combined with availability under our credit facility and access to the debt markets, will provide sufficient liquidity to fund our current obligations, projected working capital requirements, capital spending, and anticipated stock repurchases for a period that includes the next twelve months as well as the next several years. However, our ability to maintain sufficient liquidity may be affected by numerous factors, many of which are outside our control.
We have engaged in and continue to engage in the review and planning of strategic alternatives to refinance or otherwise optimize our capital structure, which alternatives may include issuing debt, equity or other securities, or entering into new credit facilities. This review and planning could result in our pursuing one or more significant corporate transactions. There can be no assurance as to when or whether we will determine to pursue any such transaction, whether any such transaction will be successful, or the effects the failure to undertake any such transaction may have on our business, including our ability to achieve our operational, strategic, and financial goals.
Critical Accounting Estimates
There have been no material changes in our critical accounting estimates as disclosed in our 2025 Form 10-K.
Recent Accounting Pronouncements
For information regarding recent accounting pronouncements, see Note 2 “Summary of Significant Accounting Policies” to the Consolidated Financial Statements.
Cautionary Disclosure Regarding Forward-Looking Statements
Certain statements contained in this Quarterly Report on Form 10-Q are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risks and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our 2025 Form 10-K and that might be contained in this Quarterly Report on Form 10-Q, which should be read in conjunction with the forward-looking statements in this Quarterly Report on Form 10-Q. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.
Non-GAAP Financial Measures and Reconciliations
We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in this Quarterly Report on Form 10-Q:
Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.
Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.
A description of special items in our non-GAAP financial measures described above are as follows:
- Restructuring expense primarily related to workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Covista’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense.
- Amortization of acquired intangible assets.
- Amortization of cloud computing implementation assets.
- Strategic advisory costs related to expanding capabilities and bringing new capacities to market to further enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic advisory costs.
- Reserves related to significant litigation.
- Loss on debt extinguishment related to amendments and repayments of our Senior Secured Notes due 2028, Term Loan B, and Revolver.
- Asset impairments related to adjusting certain operating lease assets and property and equipment as a result of adjusting carrying values to fair values.
- Debt modification costs related to refinancing our Term Loan B.
- Loss (income) from discontinued operations includes activity from ongoing litigation costs and settlements related to divestitures and the earn-outs we received.
The following tables provide a reconciliation from the most directly comparable GAAP measure to these non-GAAP financial measures. The operating income reconciliation is included in the results of operations section within this MD&A.
Net income reconciliation to adjusted net income (in thousands):
| | | Three Months Ended March 31, 2026 | | 2025 | | Nine Months Ended March 31, 2026 | | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net income (GAAP) | | $41,637 | | $60,832 | | $179,845 | | $182,853 |
| Restructuring expense | | 863 | | 510 | | 5,228 | | 2,926 |
| Amortization of acquired intangible assets | | 2,805 | | 2,805 | | 8,415 | | 8,415 |
| Strategic advisory costs | | 7,238 | | 5,100 | | 17,032 | | 5,100 |
| Loss on debt extinguishment, litigation reserve, asset impairments, and debt modification costs | | 3,828 | | 8,180 | | 4,810 | | 3,342 |
| Income tax impact on non-GAAP adjustments (1) | | (3,676) | | (4,134) | | (8,822) | | (4,821) |
| Loss (income) from discontinued operations | | 16,345 | | (38) | | 15,370 | | (4,638) |
| Adjusted net income (non-GAAP) | | $69,040 | | $73,255 | | $221,878 | | $193,177 |
(1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.
Diluted earnings per share reconciliation to adjusted earnings per share (shares in thousands):
| | | Three Months Ended March 31, 2026 | | 2025 | | Nine Months Ended March 31, 2026 | | 2025 |
|---|---|---|---|---|---|---|---|---|
| Diluted earnings per share (GAAP) | | $1.20 | | $1.59 | | $4.99 | | $4.74 |
| Effect on diluted earnings per share: | | | | | | | | |
| Restructuring expense | | 0.02 | | 0.01 | | 0.15 | | 0.08 |
| Amortization of acquired intangible assets | | 0.08 | | 0.07 | | 0.23 | | 0.22 |
| Strategic advisory costs | | 0.21 | | 0.13 | | 0.47 | | 0.13 |
| Loss on debt extinguishment, litigation reserve, asset impairments, and debt modification costs | | 0.11 | | 0.21 | | 0.13 | | 0.09 |
| Income tax impact on non-GAAP adjustments (1) | | (0.11) | | (0.11) | | (0.24) | | (0.12) |
| Loss (income) from discontinued operations | | 0.47 | | (0.00) | | 0.43 | | (0.12) |
| Adjusted earnings per share (non-GAAP) | | $1.98 | | $1.92 | | $6.16 | | $5.01 |
| Diluted shares | | 34,782 | | 38,233 | | 36,031 | | 38,583 |
(1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.
Reconciliation to adjusted EBITDA (in thousands):
| Chamberlain: | | Three Months Ended March 31, 2026 | 2025 | Increase/(Decrease) $% | | | | Nine Months Ended March 31, 2026 | 2025 | Increase/(Decrease) $% | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted operating income (GAAP) | | $47,895 | $47,493 | $402 | | 0.8% | | $107,326 | $117,628 | $(10,302) | | (8.8)% |
| Depreciation | | 6,027 | 5,350 | 677 | | | | 17,108 | 16,184 | 924 | | |
| Amortization of cloud computing implementation assets | | 2,073 | 786 | 1,287 | | | | 5,620 | 2,253 | 3,367 | | |
| Stock-based compensation | | 2,465 | 3,178 | (713) | | | | 8,709 | 10,290 | (1,581) | | |
| Adjusted EBITDA (non-GAAP) | | $58,460 | $56,807 | $1,653 | | 2.9% | | $138,763 | $146,355 | $(7,592) | | (5.2)% |
| Adjusted EBITDA margin (non-GAAP) | | 29.7% | 29.5% | | | | | 24.8% | 27.0% | | | |
| Walden: | | | | | | | | | | | | |
| Adjusted operating income (GAAP) | | $42,376 | $47,999 | $(5,623) | | (11.7)% | | $176,910 | $136,794 | $40,116 | | 29.3% |
| Depreciation | | 2,075 | 1,951 | 124 | | | | 6,089 | 5,428 | 661 | | |
| Amortization of cloud computing implementation assets | | 1,918 | 763 | 1,155 | | | | 5,023 | 2,242 | 2,781 | | |
| Stock-based compensation | | 3,374 | 3,288 | 86 | | | | 10,264 | 9,354 | 910 | | |
| Adjusted EBITDA (non-GAAP) (1) | | $49,743 | $54,001 | $(4,258) | | (7.9)% | | $198,286 | $153,818 | $44,468 | | 28.9% |
| Adjusted EBITDA margin (non-GAAP) (1) | | 26.7% | 30.3% | | | | | 33.4% | 30.1% | | | |
| Medical and Veterinary: | | | | | | | | | | | | |
| Adjusted operating income (GAAP) | | $21,502 | $17,921 | $3,581 | | 20.0% | | $63,309 | $54,170 | $9,139 | | 16.9% |
| Depreciation | | 3,109 | 2,785 | 324 | | | | 8,936 | 8,098 | 838 | | |
| Amortization of cloud computing implementation assets | | 720 | 304 | 416 | | | | 1,836 | 902 | 934 | | |
| Stock-based compensation | | 2,129 | 1,848 | 281 | | | | 6,221 | 5,613 | 608 | | |
| Adjusted EBITDA (non-GAAP) | | $27,460 | $22,858 | $4,602 | | 20.1% | | $80,302 | $68,783 | $11,519 | | 16.7% |
| Adjusted EBITDA margin (non-GAAP) | | 26.5% | 24.0% | | | | | 26.9% | 24.7% | | | |
| Home Office: | | | | | | | | | | | | |
| Adjusted operating loss | | $(9,525) | $(8,047) | $(1,478) | | (18.4)% | | $(28,937) | $(25,930) | $(3,007) | | (11.6)% |
| Depreciation | | 166 | 188 | (22) | | | | 494 | 557 | (63) | | |
| Stock-based compensation | | 1,603 | 1,949 | (346) | | | | 5,909 | 5,924 | (15) | | |
| Adjusted EBITDA | | $(7,756) | $(5,910) | $(1,846) | | (31.2)% | | $(22,534) | $(19,449) | $(3,085) | | (15.9)% |
| Covista: | | | | | | | | | | | | |
| Net income (GAAP) | | $41,637 | $60,832 | $(19,195) | | (31.6)% | | $179,845 | $182,853 | $(3,008) | | (1.6)% |
| Loss (income) from discontinued operations | | 16,345 | (38) | 16,383 | | | | 15,370 | (4,638) | 20,008 | | |
| Interest expense | | 13,629 | 13,074 | 555 | | | | 35,636 | 41,465 | (5,829) | | |
| Other income, net | | (232) | (1,898) | 1,666 | | | | (4,422) | (6,779) | 2,357 | | |
| Provision for income taxes | | 19,963 | 18,539 | 1,424 | | | | 61,504 | 51,716 | 9,788 | | |
| Depreciation and amortization | | 18,893 | 14,932 | 3,961 | | | | 53,521 | 44,079 | 9,442 | | |
| Stock-based compensation | | 9,571 | 10,263 | (692) | | | | 31,103 | 31,181 | (78) | | |
| Restructuring expense | | 863 | 510 | 353 | | | | 5,228 | 2,926 | 2,302 | | |
| Litigation reserve | | — | — | — | | | | — | (5,550) | 5,550 | | |
| Asset impairments | | — | 6,442 | (6,442) | | | | — | 6,442 | (6,442) | | |
| Strategic advisory costs | | 7,238 | 5,100 | 2,138 | | | | 17,032 | 5,100 | 11,932 | | |
| Debt modification costs | | — | — | — | | | | — | 712 | (712) | | |
| Adjusted EBITDA (non-GAAP) (1) | | $127,907 | $127,756 | $151 | | 0.1% | | $394,817 | $349,507 | $45,310 | | 13.0% |
| Adjusted EBITDA margin (non-GAAP) (1) | | 26.3% | 27.4% | | | | | 27.2% | 26.3% | | | |
(1) Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden adjusted EBITDA would have increased 25.5%, or $13.8 million, to $67.8 million and Walden adjusted EBITDA margin would have been 33.1%. Similarly, consolidated adjusted EBITDA would have increased 14.2%, or $18.2 million, to $145.9 million and consolidated adjusted EBITDA margin would have been 28.9%.
Market risk
As filed, 245 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in Covista’s market risk exposure during the first nine months of fiscal year 2026 from those set forth in Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” contained in our 2025 Form 10-K.
Controls and procedures
As filed, 849 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Based on an evaluation of our disclosure controls and procedures (as such term is defined in Exchange Act Rule 13a-15(e)) that was conducted under the supervision and with the participation of Covista’s management, including our Chief Executive Officer and Chief Financial Officer, our Chief Executive Officer and Chief Financial Officer concluded that Covista’s disclosure controls and procedures were effective as of March 31, 2026.
Changes in Internal Control over Financial Reporting
There were no changes during the third quarter of fiscal year 2026 in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 145 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to Covista’s risk factors from those set forth since Item 1A. “Risk Factors” contained in our 2025 Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-01-01 to 2026-03-31 | $487.0m | us-gaap:Revenues |
| Revenue | 9 months2025-07-01 to 2026-03-31 | $1.45bn | us-gaap:Revenues |
| Cost of revenue | 3 months2026-01-01 to 2026-03-31 | $210.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-07-01 to 2026-03-31 | $616.9m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2026-01-01 to 2026-03-31 | $184.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2025-07-01 to 2026-03-31 | $542.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-01-01 to 2026-03-31 | $91.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-07-01 to 2026-03-31 | $287.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-01-01 to 2026-03-31 | $13.6m | us-gaap:InterestExpense |
| Interest expense | 9 months2025-07-01 to 2026-03-31 | $35.6m | us-gaap:InterestExpense |
| Income tax | 3 months2026-01-01 to 2026-03-31 | $20.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-07-01 to 2026-03-31 | $61.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-01-01 to 2026-03-31 | $41.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-07-01 to 2026-03-31 | $179.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-01-01 to 2026-03-31 | $1.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-07-01 to 2026-03-31 | $4.99 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-01-01 to 2026-03-31 | $1.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-07-01 to 2026-03-31 | $5.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-01-01 to 2026-03-31 | 34,782,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-07-01 to 2026-03-31 | 36,031,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-07-01 to 2026-03-31 | $346.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-07-01 to 2026-03-31 | $50.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2025-07-01 to 2026-03-31 | $239.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2026-03-31 | $147.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-03-31 | $403.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-03-31 | $2.74bn | us-gaap:Assets |
| Current liabilities | At period end2026-03-31 | $580.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-03-31 | $1.37bn | us-gaap:Liabilities |
| Long-term debt | At period end2026-03-31 | $495.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2026-03-31 | $3.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2026-03-31 | $1.36bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-26-057163. Last ingested by Listed: Oct 29, 2026, 18:23 ET. Listed shows no prices and gives no investment advice.